Anavex Life Sciences Corp. (AVXL)

NASDAQ • Healthcare

$1.33

-$0.03 (-2.2%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$1.34

Day Range$1.29 - $1.35

Avg. Volume (3M)1.5M

Market Cap$123.2M

52 Week Range

$1.14$8.79

Next EarningsIn 30 daysNov 24, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$24M

EPS (TTM)

-$0.26

ROA (TTM)

-20.01%

Current Ratio

15.62

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-23.1%Q3 2025-$0.16

+15.4%Q4 2025-$0.11

+40.0%Q1 2026-$0.06

+200.0%Q3 2026$0.08

+62.5%Q3 2026-$0.03

Nov 24

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +62.5%

Anavex Life Sciences’ EPS topped consensus in the third fiscal quarter of 2026, with results reported August 28, 2026 based on preliminary figures, as EPS came in at -$0.03 versus an estimate of -$0.08 (topped by $0.05) and improved from -$0.16 a year ago (up +81.2%). As a clinical-stage biotechnology company developing CNS therapeutic candidates such as ANAVEX 2-73, the quarter’s bottom-line profile remained loss-making, with GAAP net income of roughly -$3.2 million, a +75.9% year-over-year improvement from about -$13.2 million, alongside GAAP operating income of about -$6.5 million. Cash flow from operations was negative at roughly -$13.5 million. Consensus for the next period calls for EPS of -$0.11.

Next report — what to expect

Anavex Life Sciences Corp. (AVXL) is scheduled to report earnings on November 24, 2026. Consensus calls for EPS of -$0.11. The company has beaten EPS in 7 of 8 most recent quarters, so traders may focus on whether that pattern continues alongside any updates that could shape expectations.

View full earnings history

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a NASDAQ-listed biotechnology company focused on developing therapeutic drug candidates for central nervous system conditions. The company is still at a clinical stage rather than a commercial one, with a drug pipeline centered on neurodegenerative, neurodevelopmental, pain, and oncology programs.

Name

Anavex Life Sciences Corp.

CEO

Terrie Kellmeyer

Website

www.anavex.com

Industry

Healthcare

Year Founded

2004

Employees

Today's Snapshot

AI-generated

AVXL closed 2.2% lower at 1.33, in line with a weaker sector. Volume was about half of its usual level.

Trading Volume

Below 10d avg (1.3M)

626.1K

vs S&P 500 Today

Underperforming Market

-1.69%

Updated: October 23, 2026 at 20:15 UTC

Technical Indicators

1 Buy2 Neutral5 Sell

AVXL is trading at 1.33 and shows a pronounced bearish structure driven by a very strong directional trend and weak volume. The ADX is elevated, signaling a powerful trend, while price sits well under its short, medium and long moving averages and the 200-day level, underscoring broad technical weakness. Momentum measures are negative and the MACD print is below zero, even as RSI reads as oversold, suggesting the down-move has been sharp. Volatility is meaningful with ATR near a double-digit percentage of price and OBV is heavily negative. Technical takeaway: Strong Sell — dominant downtrend with weak volume and elevated volatility.

All signals